• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of asthma >Omalizumab reduces corticosteroid use in patients with severe allergic asthma: Real-life experience in israel
【24h】

Omalizumab reduces corticosteroid use in patients with severe allergic asthma: Real-life experience in israel

机译：奥马珠单抗减少严重过敏性哮喘患者的皮质类固醇激素使用：以色列的现实生活经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective. Approved by the FDA in 2003, omalizumab is the first recombinant humanized monoclonal anti-immunoglobulin E antibody developed for the treatment of allergic asthma. Due to the heterogeneity of asthma symptoms, investigation of the efficacy of omalizumab in patients outside controlled trials is particularly important. The purpose of the current study was to evaluate the efficacy of omalizumab as an add-on treatment for allergic asthma in a real-life setting in Israel. Methods. This was a retrospective study based on patient records and computerized database for drug dispensing, emergency room visits, and hospital admissions. Results. The sample comprised 33 individuals (18 men, 15 women; mean age 50.0 ± 12.2, range 2579) who were treated with omalizumab for severe allergic asthma for a duration of at least 16 weeks. After the initiation of omalizumab therapy, the number of patients who used oral or injected corticosteroids decreased (p < .003, .03, respectively), as did the median dosage of oral corticosteroids (p < .02). Visits to the emergency room decreased from an incidence of 0.526 visits per person-year to an incidence of 0.246 per person-year (p < .05). No adverse reactions to omalizumab were observed. Conclusion. Omalizumab as an add-on therapy reduced the use of corticosteroids and improved the control of asthma, as evidenced by reduced asthma-related emergency room visits. This study supports both controlled and uncontrolled studies that have demonstrated the efficacy and safety of omalizumab, and particularly those that demonstrated effectiveness among severe asthma patients. "Real-life" studies are important to identify patients who will most benefit from omalizumab therapy.
机译：目的。 omalizumab是FDA在2003年批准的，是首个用于治疗变应性哮喘的重组人源化单克隆抗免疫球蛋白E抗体。由于哮喘症状的异质性，在对照试验之外研究奥马珠单抗对患者的疗效尤为重要。本研究的目的是评估在以色列的真实生活中，奥马珠单抗作为过敏性哮喘的附加疗法的疗效。方法。这是一项基于患者记录和计算机数据库的回顾性研究，用于药物分配，急诊室就诊和住院。结果。样本包括33例接受奥马珠单抗治疗的严重过敏性哮喘患者，持续时间至少16周（平均年龄为50.0±12.2，范围2579）。在开始奥马珠单抗治疗后，口服或注射皮质类固醇的患者人数减少（分别为p <.003，.03），口服皮质类固醇的中位剂量也有所减少（p <.02）。到急诊室就诊的人次从每人年0.526次下降到每人年0.246次（p <.05）。没有观察到对奥马珠单抗的不良反应。结论。奥马珠单抗作为一种辅助疗法减少了皮质类固醇的使用并改善了对哮喘的控制，这与减少与哮喘有关的急诊就诊有关。该研究支持对照和非对照研究，这些研究已经证明了奥马珠单抗的功效和安全性，特别是那些在重度哮喘患者中证明有效的药物。 “现实生活”研究对于确定最受益于奥马珠单抗治疗的患者很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号